Prevention And Treatment Of Chronic Heart And Kidney Disease Via Epidemiological, Pharmacol Device And Cell-Based Approaches
Funder
National Health and Medical Research Council
Funding Amount
$5,795,334.00
Summary
Heart failure describes where the heart cannot pump adequately to meet the needs of the body. This condition has a high mortality despite recent advances in therapy, therefore, there is an urgent need for new approaches to this condition. The present grant aims to: (1) identify patients at high-risk for future development of this condition where early intervention with drugs may reduce or prevent the development of new heart failure; (2) use novel drugs, devices and stem cell therapies to identi ....Heart failure describes where the heart cannot pump adequately to meet the needs of the body. This condition has a high mortality despite recent advances in therapy, therefore, there is an urgent need for new approaches to this condition. The present grant aims to: (1) identify patients at high-risk for future development of this condition where early intervention with drugs may reduce or prevent the development of new heart failure; (2) use novel drugs, devices and stem cell therapies to identify ways to better treat patients with existing disease; (3) focus on the effect of heart failure on the kidney and vice versa via early diagnosis and treatment strategiesRead moreRead less
The team has been at the forefront of research on type 1 diabetes for over a decade. This form of diabetes is a major chronic disease from childhood, as well as accounting for at least 10% of adult-onset diabetes. It occurs when the body�s immune system attacks and destroys the beta cells in the pancreas that make insulin, the hormone that controls the level of glucose in the blood. The team was one of the first in the world, and is the only one in Australia, to develop screening programs to tes ....The team has been at the forefront of research on type 1 diabetes for over a decade. This form of diabetes is a major chronic disease from childhood, as well as accounting for at least 10% of adult-onset diabetes. It occurs when the body�s immune system attacks and destroys the beta cells in the pancreas that make insulin, the hormone that controls the level of glucose in the blood. The team was one of the first in the world, and is the only one in Australia, to develop screening programs to test and identify people at risk for type 1 diabetes. They showed that the underlying disease could start years before symptoms occurred and discovered genes that determine the rate at which the underlying disease progresses. They have also found evidence that the disease may be triggered by gut viruses called rotaviruses in genetically-susceptible individuals. They showed that type 1 diabetes could be prevented in a mouse model by getting the immune system to make a protective response to insulin, and then went on to apply this in at-risk humans in a controlled trial of intranasal insulin, the first of its kind. They have used genetic techniques not only to pinpoint the mechanisms responsible for killing the beta cells but also to modify the beta cells to make them resistant to attack by these mechanisms. The multidisciplinary approach of the team will be directed to further understanding the genetic and environmental factors underlying type 1 diabetes and the immune mechanisms, particularly involving special white blood cells called T cells, that kill beta cells. A molecular target of the immune attack, the parent of insulin called proinsulin, will be used, paradoxically, as a tool to regulate the immune system and avert the attack. This will be achieved by giving proinsulin via the mucosa of the naso-respiratory tract or via the bone marrow-derived stem cells, initiallyin the mouse model as a test of feasibility for human application. In parallel with these approaches to prevention, specially constructed viruses will be used to transfer several new genes into beta cells to improve their resistance to immune attack, so that they can be transplanted into people with established diabetes without the need for potentially toxic drugs that suppress the immune system overall. The integrated research of the team is helping to provide a sound, rational base for the eventual prevention and cure of type 1 diabetes.Read moreRead less
Development Of Innovative Approaches To Manage Insect-transmitted Diseases
Funder
National Health and Medical Research Council
Funding Amount
$4,435,142.00
Summary
This program grant focuses on the development of new methods to control mosquito-borne diseases, including those caused by dengue, Japanese encephalitis, and chikungunya viruses. We are investigating whether the introduction of Wolbachia micro-organisms into mosquitoes can be used to selectively eliminate old mosquitoes and reduce transmission of human pathogens. We will also determine whether Wolbachia have any non-lethal affects on mosquito behaviours such as dispersal and biting activity whic ....This program grant focuses on the development of new methods to control mosquito-borne diseases, including those caused by dengue, Japanese encephalitis, and chikungunya viruses. We are investigating whether the introduction of Wolbachia micro-organisms into mosquitoes can be used to selectively eliminate old mosquitoes and reduce transmission of human pathogens. We will also determine whether Wolbachia have any non-lethal affects on mosquito behaviours such as dispersal and biting activity which determine the level of contact between mosquitoes and humans.Read moreRead less
Type 1 diabetes (T1D) is a major chronic disease affecting over 100,000 Australians. Its treatment and complications impose a significant burden on affected individuals and their families and on the health system. T1D occurs when the immune system attacks insulin-producing cells in the islet cells of the pancreas. The team has developed ways to identify at-risk people, defined immune and genetic causes of T1D and is undertaking prevention trials and Australia's first islet transplant program. Th ....Type 1 diabetes (T1D) is a major chronic disease affecting over 100,000 Australians. Its treatment and complications impose a significant burden on affected individuals and their families and on the health system. T1D occurs when the immune system attacks insulin-producing cells in the islet cells of the pancreas. The team has developed ways to identify at-risk people, defined immune and genetic causes of T1D and is undertaking prevention trials and Australia's first islet transplant program. Their multidisciplinary research is taking us closer to the prevention and cure of T1D.Read moreRead less
Host Parasite Interactions: Disease, Pathogenesis And Control
Funder
National Health and Medical Research Council
Funding Amount
$13,738,897.00
Summary
Our program will investigate two major global parasitic diseases: malaria and leishmaniasis. We will explore how the parasites identify and invade the host. This is a critical stage of the infection and we will characterise proteins involved as they are potential targets for drugs and vaccines against the parasites. Many of these recognition and interaction components are excellent candidates for the development of vaccines to interrupt the cycle of infection. We are also unravelling metabolic p ....Our program will investigate two major global parasitic diseases: malaria and leishmaniasis. We will explore how the parasites identify and invade the host. This is a critical stage of the infection and we will characterise proteins involved as they are potential targets for drugs and vaccines against the parasites. Many of these recognition and interaction components are excellent candidates for the development of vaccines to interrupt the cycle of infection. We are also unravelling metabolic pathways unique to the parasites using a mixture of genetic and computational tools complemented with sophisticated instrumentation to chemically identify the parasite�s entire repertoire of metabolic compounds. These pathways, absent from human hosts, are also highly vulnerable and we will feed the key steps into the drug development facet of the program. Our program also looks at how the parasites cause disease and how the host responds to the disease. We will explore the reactions of the immune system to infection and consequences of the body�s (often only partially successful) attempts to fight off the disease.Read moreRead less
Immunity And Pathogenesis In Tropical And Infectious Diseases: Implications For Vaccines And
Funder
National Health and Medical Research Council
Funding Amount
$15,794,553.00
Summary
Malaria, streptococcal diseases, helminthiases and scabies are diseases of indigenous people on a massive scale, which lack vaccines. We aim to understand the pathogenesis of these diseases and develop vaccines and other treatments to combat them. Team includes senior experts on infectious diseases with long collaborative histories and younger members with impressive credentials. The work proposed also concerns inventive new ways of making such vaccines by novel chemical methods and aspects of d ....Malaria, streptococcal diseases, helminthiases and scabies are diseases of indigenous people on a massive scale, which lack vaccines. We aim to understand the pathogenesis of these diseases and develop vaccines and other treatments to combat them. Team includes senior experts on infectious diseases with long collaborative histories and younger members with impressive credentials. The work proposed also concerns inventive new ways of making such vaccines by novel chemical methods and aspects of delivery.Read moreRead less
Advances In Clinical Trials Research And Evidence Based Decision Making
Funder
National Health and Medical Research Council
Funding Amount
$6,712,859.00
Summary
The NHMRC Clinical Trials Centre at the University of Sydney aims to use clinical trials and methodological research in trials to improve health in Australia and internationally It is a member of many international collaborative trials groups, especially in heart disease and cancer. A particular area of interest is patient preferences and decision making, particularly in cancer. The Clinical Trial Centre is active in using data from its own and other clinical trials in combined analyses to arriv ....The NHMRC Clinical Trials Centre at the University of Sydney aims to use clinical trials and methodological research in trials to improve health in Australia and internationally It is a member of many international collaborative trials groups, especially in heart disease and cancer. A particular area of interest is patient preferences and decision making, particularly in cancer. The Clinical Trial Centre is active in using data from its own and other clinical trials in combined analyses to arrive at better evidence.Read moreRead less